Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Best Practice & Research. Clinical Gastroenterology|December 21, 2025
Targeted and individualized dietary interventions in disorders of gut-brain interactionKaren Routhiaux, Tom van Gils, Lukas Michaja Balsiger
Frontiers in Immunology|February 9, 2026
Emerging diagnostic and therapeutic opportunities in food allergyLukas Michaja Balsiger, Oliver M Würgler, Hugh A Sampson, et al.
The Lancet. Gastroenterology & Hepatology|January 26, 2023
Understanding and managing patients with overlapping disorders of gut-brain interactionLukas Michaja Balsiger, Florencia Carbone, Karlien Raymenants, et al.
Digestive Diseases and Sciences|March 19, 2024
Added Value of 13C Analysis in Breath Tests in H2-Negative Subjects to Diagnose Lactose Malabsorption: A Proof of Concept StudyLukas Michaja Balsiger, Els Houben, Tim Vanuytsel, et al.
Neurogastroenterology and Motility|September 24, 2024
Review: Food-induced mucosal alterations visualized using endomicroscopyLukas Michaja Balsiger, Monica Rusticeanu, Jost Langhorst, et al.
Nutrients|January 11, 2024
Nutrition and Disorders of Gut-Brain InteractionEmidio Scarpellini, Lukas Michaja Balsiger, Bert Broeders, et al.
Gut|August 13, 2025
Global prevalence and gastrointestinal symptom burden of individuals with a history of cholecystectomyBo Konings, Lukas Michaja Balsiger, Johann Pall Hreinsson, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2023
Prevalence of delayed gastric emptying in patients with gastroparesis-like symptomsI-Hsuan Huang, Jolien Schol, Florencia Carbone, et al.
Clinical and Translational Gastroenterology|October 16, 2025
Symptoms but Not Physiology Differentiate Functional Dyspepsia With or Without Overlapping Gastrointestinal DisordersMatthias Ceulemans, Lucas Wauters, Bert Broeders, et al.
The American Journal of Gastroenterology|November 26, 2024
A Phase II, Multicentric, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhea-Predominant Irritable Bowel SyndromeLukas Michaja Balsiger, Javier Santos, Jordi Serra, et al.
Pageof 2